Lung cancer hope: drug combo targets resistant tumors
NCT ID NCT04691817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding tocilizumab to atezolizumab can shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. About 28 adults will receive the combination and be monitored for side effects and response. The goal is to find a new treatment option for this hard-to-treat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could reveal how lung cancer evolves during treatment
- Scientists probe how lung cancer outsmarts key drugs
- Early lung cancer drug combo trial halted after just 6 patients
- Blood test could guide who needs extra cancer therapy after lung surgery
- Tiny study probes risks of lung cancer combo therapy
- Blood markers may reveal which lung cancer patients stay Cancer-Free after treatment